Kai Rejeski: Delineating the prognostic significance of immune reconstitution in CAR-T recipients
Kai Rejeski, Research Fellow at Memorial Sloan Kettering Cancer Center, shared an article by Sophia Stock on X:
“Fantastic work by Sophia Stock on our LMU Munich Immunotherapy in Hematology LMU Klinikum München study delineating the prognostic significance of immune reconstitution (IR) in CAR-T recipients – out today in HemaSphere Journal (IF = 11.9).
Check out open access link.”
Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.
Authors: Sophia Stock, et al.
Kai Rejeski is a Visiting Investigator and Research Fellow at Memorial Sloan Kettering Cancer Center, as well as a Resident Physician and Clinical Fellow at LMU München Clinic. His research focuses on mapping and modeling CAR T-cell toxicities and using AI-based morphometric techniques to enhance clinical decision-making and improve the safety of cellular therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023